/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology..

/ -- 艾伯维（AbbVie，纽约证券交易所代码：ABBV）与处于临床后期的生物技术公司ADARx Pharmaceuticals今日宣布达成一项合作与许可选择协议，旨在开发针对多个疾病领域的小干扰RNA（siRNA）治疗药物，涵盖神经科学、免疫学和肿瘤学等领域。

siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates the expression of genes. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins..

小干扰RNA（siRNA）是一类能够调控基因表达和蛋白质生成的分子。与抗体和小分子等传统形式不同，siRNA通过靶向编码致病蛋白的信使RNA（mRNA），从而抑制这些基因的表达。这类分子的设计目的是阻止致病蛋白的生成。

The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts..

该战略合作将利用ADARx的RNA发现专业知识及其专有的siRNA技术，这项技术有可能实现持续且精准的mRNA沉默。AbbVie将根据需要贡献其在抗体工程、抗体药物偶联物（ADC）和组织递送方法方面的专业知识，以增强ADARx的发现工作。

'siRNA is a promising genetic medicine approach for silencing disease-causing genes, but challenges still remain in targeting and delivering siRNA effectively,' said

“siRNA是一种有前途的基因药物方法，可以沉默致病基因，但在有效靶向和递送siRNA方面仍然存在挑战，”

Jonathon Sedgwick

乔纳森·塞德威克

, Ph.D., senior vice president and global head, discovery research, AbbVie. 'We are very pleased to collaborate with ADARx, leveraging their proprietary RNA technology alongside our antibody, ADC, and therapeutic area research and development expertise to bring siRNA forward as a potential novel therapeutic modality alongside our other established approaches.

博士，高级副总裁兼全球负责人，发现研究，艾伯维。 “我们非常高兴与ADARx合作，利用他们专有的RNA技术以及我们在抗体、ADC和治疗领域研发方面的专业知识，将siRNA作为一种潜在的新型治疗方式，与我们其他已建立的方法一起推进。”

Together, we're committed to developing innovative solutions for difficult-to-treat diseases across neuroscience, immunology and oncology.'.

我们共同致力于在神经科学、免疫学和肿瘤学领域开发针对难治性疾病的创新解决方案。

'This collaboration with AbbVie further validates the differentiated RNA technology that we have developed at ADARx and has the potential to unlock tremendous clinical and commercial potential across multiple disease areas. AbbVie's research and development expertise combined with its global commercial reach make them the ideal strategic collaborator to accelerate these programs for the potential benefit of patients worldwide,' said .

“与AbbVie的合作进一步验证了我们在ADARx开发的差异化RNA技术，并有潜力在多个疾病领域释放巨大的临床和商业潜力。AbbVie的研发专业知识及其全球商业覆盖使他们成为理想的合作伙伴，可以加速推进这些项目，为全球患者带来潜在益处。”

Zhen Li

李珍

, Ph.D., co-founder, president and chief executive officer of ADARx. 'In addition to this strategic collaboration with AbbVie, ADARx continues to advance a deep pipeline of wholly-owned clinical-stage programs that span complement-mediated, cardiovascular and thrombotic diseases and various preclinical discovery programs including in obesity and neurodegeneration.'.

博士，ADARx的联合创始人、总裁兼首席执行官表示：“除了与AbbVie的战略合作之外，ADARx还继续推进一系列全资拥有的临床阶段项目，涵盖补体介导疾病、心血管和血栓性疾病，以及包括肥胖症和神经退行性疾病在内的多种临床前发现项目。”

Under the terms of the agreement, ADARx will receive a

根据协议条款，ADARx将获得

$335 million

3.35亿美元

upfront payment and will be eligible to receive several billion dollars in additional contingent payments including option-related fees and milestone payments, as well as tiered royalties.

预先付款，并有资格获得数十亿美元的额外或有付款，包括与期权相关的费用和里程碑付款，以及分级特许权使用费。

About AbbVie

关于艾伯维

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.

艾伯维的使命是发现并提供创新的药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在包括免疫学、肿瘤学、神经科学和眼科等多个关键治疗领域对人们的生活产生显著影响，并通过我们的艾尔建美学产品组合提供相关产品和服务。

About ADARx Pharmaceuticals

关于ADARx制药公司

ADARx Pharmaceuticals, Inc. is a late clinical-stage biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

ADARx Pharmaceuticals, Inc.是一家处于临床后期阶段的生物技术公司，致力于将前沿科学转化为覆盖广泛治疗领域的下一代RNA药物。我们的目标是通过高度选择性的RNA靶向疗法控制特定疾病驱动因子的表达，为迫切未满足医疗需求的患者提供改变生命的治疗方案。

We are focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, initially developing our product candidates for the treatment of complement-mediated, genetic, cardiovascular, central nervous system and metabolic (obesity) diseases.

我们专注于推进和扩展一条深入的、高效、持久且选择性强的RNA靶向治疗候选药物管线，最初开发我们的产品候选药物用于治疗补体介导的遗传性、心血管、中枢神经系统和代谢（肥胖）疾病。